Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (HK:1276)
:1276
Want to see HK:1276 full AI Analyst Report?
Top Page
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
(1276)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$58.00
â–¼(-8.45% Downside)
Action:N/A
Date:06/12/26
The score is driven up by strong financial performance (profitability, cash generation, and very low leverage). It is held back by weak technical momentum (price below key moving averages with negative MACD) and a relatively expensive valuation (high P/E with a modest dividend yield).
Positive Factors
Conservative balance sheet
Extremely low debt relative to equity gives durable financial flexibility: it reduces solvency risk, supports continued R&D funding and capacity to withstand sector shocks, and enables strategic investments or partnerships without forcing capital raises that dilute shareholders.
Negative Factors
Moderate top-line growth
Top-line expansion is modest, which limits leverage from scale and constrains long-term earnings upside if new product launches or geographic expansion falter. Sustained value creation will require either faster organic growth or successful innovation outperformance.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low debt relative to equity gives durable financial flexibility: it reduces solvency risk, supports continued R&D funding and capacity to withstand sector shocks, and enables strategic investments or partnerships without forcing capital raises that dilute shareholders.
Read all positive factors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$369.45B
Dividend Yield0.36%
Average Volume (3M)3.62M
Price to Earnings (P/E)38.9
Beta (1Y)0.60
Revenue Growth13.59%
EPS GrowthN/A
CountryHK
Employees20,602
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.38
Shares Outstanding258,197,600
10 Day Avg. Volume2,417,952
30 Day Avg. Volume3,618,442
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$88.60Price Target Upside39.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$41.46B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncolo...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products, generating revenue from the commercialization of its proprietary drug portfolio through distribution to hospitals, pharmacies, and other healthcare channels. A key revenue strea...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
88
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.87B | 35.19B | 29.77B | 25.26B | 24.23B | 31.02B |
| Gross Profit | 30.72B | 30.33B | 25.68B | 21.36B | 20.26B | 26.20B |
| EBITDA | 10.24B | 10.64B | 8.46B | 5.95B | 5.19B | 5.19B |
| Net Income | 8.95B | 8.58B | 6.74B | 4.76B | 4.45B | 5.46B |
Balance Sheet | ||||||
| Total Assets | 81.17B | 77.73B | 53.33B | 48.21B | 47.57B | 48.03B |
| Cash, Cash Equivalents and Short-Term Investments | 46.26B | 45.69B | 26.69B | 22.95B | 20.06B | 22.90B |
| Total Debt | 42.24M | 48.18M | 73.44M | 692.54M | 1.91B | 1.36B |
| Total Liabilities | 8.14B | 8.98B | 4.30B | 2.99B | 4.31B | 4.38B |
| Stockholders Equity | 72.44B | 68.17B | 48.42B | 44.55B | 42.47B | 42.82B |
Cash Flow | ||||||
| Free Cash Flow | 9.36B | 9.20B | 5.80B | 6.82B | -827.89M | 3.39B |
| Operating Cash Flow | 12.66B | 12.50B | 7.90B | 8.46B | 1.44B | 5.40B |
| Investing Cash Flow | -3.96B | -3.05B | -2.03B | 1.35B | 444.51M | -559.25M |
| Financing Cash Flow | 9.70B | 8.66B | -1.65B | -3.48B | -363.05M | -1.62B |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$173.80B | 26.72 | 16.71% | 0.97% | 22.62% | 26.23% | |
69 Neutral | HK$369.45B | 38.94 | 13.37% | 0.36% | 13.59% | ― | |
68 Neutral | HK$248.72B | 57.96 | 12.04% | ― | 37.65% | ― | |
61 Neutral | HK$130.63B | 130.89 | 4.82% | ― | 38.55% | ― | |
55 Neutral | HK$75.95B | 28.37 | 7.24% | 1.40% | 10.20% | 30.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$76.73B | -59.21 | -14.26% | ― | 44.03% | -108.83% |
* Healthcare Sector Average
HK:1276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
52.95
-2.21
-4.00%
HK:1177
Sino Biopharmaceutical
4.26
-0.95
-18.17%
HK:1801
Innovent Biologics
75.15
-2.20
-2.84%
HK:9926
Akeso, Inc.
83.30
-9.20
-9.95%
HK:3692
Hansoh Pharmaceutical Group Company Limited
28.66
-0.12
-0.42%
HK:6160
BeOne Medicines Ltd
165.90
18.50
12.55%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Corporate Events
Hengrui Pharma Wins NMPA Approval for First Domestic New-Generation URAT1 Inhibitor
May 28, 2026
Jiangsu Hengrui Pharmaceuticals has obtained marketing approval from China’s National Medical Products Administration for its self-developed Class 1 innovative drug Ruzinurad Tablets (SHR4640), a highly selective new-generation URAT1 inhibit...
Hengrui Pharma seals global collaboration and licensing deal with Bristol-Myers Squibb
May 12, 2026
Jiangsu Hengrui Pharmaceuticals has entered into Global Strategic Collaboration and License Agreements with Bristol-Myers Squibb, marking a new phase of cross-border cooperation between the Chinese drugmaker and the U.S. pharmaceutical group. The ...
Hengrui Pharma Sets Formal Remuneration and Evaluation Committee to Bolster Governance
Apr 29, 2026
Jiangsu Hengrui Pharmaceuticals has established a Remuneration and Evaluation Committee under its board to strengthen governance around pay and performance oversight for directors and senior management. The committee’s framework defines its ...
Hengrui Pharma Sets Nomination Committee to Tighten Board Governance
Apr 29, 2026
Jiangsu Hengrui Pharmaceuticals has established a Nomination Committee under its board to formalize the selection and review of directors and senior management, aiming to optimize board composition and strengthen corporate governance. The committe...
Hengrui Pharma Assumes KiOmed License from Hansoh in Connected Deal
Apr 29, 2026
Jiangsu Hengrui Pharmaceuticals has entered into a novation and transfer arrangement to assume all rights and obligations under a licensing agreement previously held by Hansoh-related entities with Belgian firm KiOmed. The change makes Hengrui the...
Jiangsu Hengrui Sets Detailed Mandate for Board Audit Committee
Apr 29, 2026
Jiangsu Hengrui Pharmaceuticals has established an Audit Committee under its board of directors, defining a detailed mandate to strengthen corporate governance and oversight. The committee is tasked with pre-audit review, supervision of financial ...
Hengrui Pharmaceuticals Posts Double-Digit Profit Growth in Strong Q1 2026
Apr 22, 2026
Jiangsu Hengrui Pharmaceuticals reported solid year-on-year growth for the first quarter of 2026, with operating revenue rising 13% to RMB 8.14 billion and net profit attributable to shareholders climbing nearly 22% to RMB 2.28 billion. The compan...
Jiangsu Hengrui Sets 2025 Final Dividend and Tax Terms for H Shares
Apr 17, 2026
Jiangsu Hengrui Pharmaceuticals has declared a final ordinary cash dividend for the year ended 31 December 2025, set at RMB 2 per 10 shares for its H-shareholders, following approval on 16 April 2026. The Hong Kong default payment will be HKD 2.28...
Jiangsu Hengrui Sets 2025 Final Dividend and Record Date for H Shareholders
Apr 17, 2026
Jiangsu Hengrui Pharmaceuticals has approved a 2025 final cash dividend of RMB2 per 10 shares, payable in Renminbi for A shares and in Hong Kong dollars for H shares based on a set exchange rate, resulting in HK$2.2828 per 10 H shares. The dividen...
Hengrui Pharma Shareholders Approve Dividends, Board Changes at 2025 AGM
Apr 16, 2026
Jiangsu Hengrui Pharmaceuticals reported that all resolutions at its 2025 annual general meeting on April 16, 2026, were approved by poll, confirming shareholder support for the company’s proposed corporate actions. The meeting covered matte...
Jiangsu Hengrui Outlines Board Composition and Key Governance Committees
Apr 16, 2026
Jiangsu Hengrui Pharmaceuticals has disclosed the current composition of its board of directors, listing six executive directors, one non-executive director and four independent non-executive directors. The mix of roles indicates a broad governanc...
Jiangsu Hengrui Schedules Board Meeting to Approve First-Quarter 2026 Results
Apr 9, 2026
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for April 22, 2026, to review and approve the quarterly results for the three months ended March 31, 2026, and to authorize their publication. The announcement signals the upcoming disc...
Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results
Mar 25, 2026
Jiangsu Hengrui Pharmaceuticals has released its audited annual results for the year ended 31 December 2025, making its full 2025 annual report available to investors and the public via the Hong Kong stock exchange website and the company’s ...
Jiangsu Hengrui Pharmaceuticals Proposes Final 2025 Dividend
Mar 25, 2026
Jiangsu Hengrui Pharmaceuticals has proposed a final ordinary cash dividend of RMB 2 per 10 shares for the financial year ended 31 December 2025, with shareholder approval scheduled for 16 April 2026. Details for Hong Kong investors, including pay...
Hengrui Pharma Sets 2025 AGM to Approve Dividends and 20% Share Issuance Mandate
Mar 25, 2026
Jiangsu Hengrui Pharmaceuticals has convened its 2025 annual general meeting for April 16, 2026 in Shanghai, where shareholders will review the 2025 board work report and annual report, decide on the profit distribution plan, and authorize the boa...
Jiangsu Hengrui Boosts Investment in Shanghai Regenelead via RMB750 Million Capital Increase
Mar 25, 2026
Jiangsu Hengrui Pharmaceuticals has agreed to participate in a RMB750 million capital increase for its associate Shanghai Regenelead, alongside Hengrui Group, Shengdi Biomedical Fund and Shenzhen Yingtai, raising Regenelead’s registered capi...
Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug
Mar 20, 2026
Jiangsu Hengrui Pharmaceuticals’ subsidiary Suzhou Suncadia Biopharmaceuticals has secured approval from China’s National Medical Products Administration for a new indication of its self-developed Class 1 innovative biologic, trastuzum...
Hengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use
Mar 13, 2026
Jiangsu Hengrui Pharmaceuticals has obtained approval from China’s National Medical Products Administration to add a new indication for its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The therapy, a prescription oral...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.